Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Fineline Cube Dec 10, 2025
Company Deals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Fineline Cube Dec 10, 2025
Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025
Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Fineline Cube Dec 11, 2025
Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Fineline Cube Dec 10, 2025
Company Drug

Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment

Fineline Cube Aug 11, 2025

German pharmaceutical giant Boehringer Ingelheim (BI) announced that its HERNEXEOS (zongertinib tablets) has received accelerated...

Company Deals

Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets

Fineline Cube Aug 11, 2025

China-based Lepu Biopharma Co., Ltd. (HKG: 2157) announced on August 1, 2025, that it has...

Company Deals

Tigermed Partners with Africare BioPharma to Enhance Africa’s Clinical Research Capabilities

Fineline Cube Aug 11, 2025

On August 8, 2025, Hangzhou Tigermed Consulting (SHE: 300347, HKG: 3347), a China-based contract research...

Company Drug

Johnson & Johnson’s Rybrevant Approved by China’s NMPA for EGFR-Mutant NSCLC Treatment

Fineline Cube Aug 11, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China’s National Medical Products Administration...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors

Fineline Cube Aug 8, 2025

China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced that it has received a Drug Clinical Trial...

Company

Viatris Reports Q2 Revenue Drop, Sees Growth in Greater China Amid Global Decline

Fineline Cube Aug 8, 2025

US-based generics firm Viatris Inc. (NASDAQ: VTRS) reported Q2 2025 financial results, showing a 7%...

Company Deals Drug

Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter

Fineline Cube Aug 8, 2025

China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License...

Company Drug

Teleflex’s Rüsch EZ-Blocker Gets NMPA Approval for China Market

Fineline Cube Aug 8, 2025

US-based Teleflex Incorporated (NYSE: TFX) announced that its Rüsch EZ-Blocker single-use bronchial blocker has received...

Company Deals

Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million

Fineline Cube Aug 8, 2025

China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare...

Company Drug

Haisco’s HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases

Fineline Cube Aug 8, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company

HutchMed Reports 9% Revenue Dip in H1 2025; FRUZAQLA Sales Grow Despite Overall Decline

Fineline Cube Aug 8, 2025

Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced its financial results for...

Company Deals

Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization

Fineline Cube Aug 8, 2025

Chengdu Westgene Biopharma announced the establishment of a strategic partnership with Shenzhen BGI Huo-Yan Engineering...

Company Drug

Henlius’ HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment

Fineline Cube Aug 8, 2025

China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration...

Company Medical Device

Cryofocus Medtech’s Cryoadhesion System Gains NMPA Approval for Commercialization

Fineline Cube Aug 8, 2025

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced that it has received approval from China’s...

Company

Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products

Fineline Cube Aug 8, 2025

China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced its financial results for the...

Company Drug

Sino Biopharmaceutical’s LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors

Fineline Cube Aug 8, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed LM-24C5 has received clinical trial...

Company Drug

Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data

Fineline Cube Aug 8, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) reported another strong quarterly performance with...

Company

Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales

Fineline Cube Aug 7, 2025

US-based biopharma Amgen Inc. (NASDAQ: AMGN) released its Q2 2025 financial results, showing a 9%...

Others

Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX

Fineline Cube Aug 7, 2025

Guangdong China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main...

Company Drug Policy / Regulatory

NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender

Fineline Cube Aug 7, 2025

The National Healthcare Security Administration (NHSA) has released Q&As on the medical institutions’ volumes filing...

Posts pagination

1 … 47 48 49 … 596

Recent updates

  • Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing
  • D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
  • Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
  • Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer
  • Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.